Clinical trial
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase…
NCT00272740 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00272740 |
|---|---|
| Title | SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer |
| Official title | An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 93 |
| Start date | Mar 1, 2000 |
| First posted | Jan 9, 2006 |
| Last update posted | Feb 9, 2007 |
| Countries | Belgium, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: